2018
Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis
Messacar K, Sillau S, Hopkins SE, Otten C, Wilson-Murphy M, Wong B, Santoro JD, Treister A, Bains HK, Torres A, Zabrocki L, Glanternik JR, Hurst AL, Martin JA, Schreiner T, Makhani N, DeBiasi RL, Kruer MC, Tremoulet AH, Van Haren K, Desai J, Benson LA, Gorman MP, Abzug MJ, Tyler KL, Dominguez SR. Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis. Neurology 2018, 92: e2118-e2126. PMID: 30413631, PMCID: PMC6512883, DOI: 10.1212/wnl.0000000000006670.Peer-Reviewed Original ResearchConceptsAcute flaccid myelitisSerious adverse eventsFluoxetine-treated patientsEfficacy of fluoxetineEV-D68Initial examinationPoor long-term outcomesImproved neurologic outcomeMulticenter cohort studyClass IV evidenceAdverse effect ratesDose of fluoxetinePropensity-adjusted analysisLong-term outcomesUnexposed patientsNeurologic outcomeUntreated patientsAdverse eventsCohort studyPrimary outcomeUS patientsStudy criteriaEnterovirus D68PatientsEffect rate
2017
MRI findings of optic pathway involvement in Miller Fisher syndrome in 3 pediatric patients and a review of the literature
Malhotra A, Zhang M, Wu X, Jindal S, Durand D, Makhani N. MRI findings of optic pathway involvement in Miller Fisher syndrome in 3 pediatric patients and a review of the literature. Journal Of Clinical Neuroscience 2017, 39: 63-67. PMID: 28209311, DOI: 10.1016/j.jocn.2016.12.049.Peer-Reviewed Original ResearchConceptsMiller Fisher syndromeOptic pathway involvementGuillain-Barré syndromeCranial nerve enhancementPediatric patientsFisher syndromeNerve enhancementPathway involvementCranial nerve involvementNerve involvementAcute illnessDemyelinating conditionMRI findingsBrighton criteriaClinical manifestationsOptic pathwayCase reportCranial nervesBrain MRIPatientsSyndromeInvolvementFindingsNerveIllness